Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Halma makes 'strong progress' in H1, hikes FY revenue guidance

(Sharecast News) - Life-saving technology company Halma said on Thursday that it had made "strong progress" in the first half, leading the group to increase its full-year revenue guidance. Halma continues to expect "low double digit" organic constant currency revenue growth for the year ending 31 March 2026, compared to its previous guidance of upper single digit growth, while adjusted EBIT margins were expected to be "modestly above" the middle of its 19-23% target range.

The FTSE 100-listed firm stated that its "strong underlying cash generation and robust financial position" was supporting continued strategic investment in future organic growth, as well as providing capacity to fund acquisitions.

In the first half of the year, Halma expects cash conversion to reflect incremental growth investment in working capital as well as capital investments across the group, while FY cash conversion was expected to be more in line with its KPI of 90%.

Halma added that its M&A pipeline remained active, with two acquisitions completed so far this financial year for a total consideration of £130.5m. It also confirmed the disposal of AAI, which generated £10m in proceeds, net of disposal costs.

"We have made strong progress in the first half of this financial year, against a backdrop of varied market conditions and a challenging economic and geopolitical environment," said Halma.

"Our continued delivery of strong, compounding growth and returns reflects the benefits of our sustainable growth model, including our participation in diverse markets whose growth is supported by long-term drivers, the exceptional talent in our companies, and the autonomy we give our companies and people to respond rapidly to changing market conditions."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.